Posted 10/2/2013 12:41 AM (GMT 0)
Dispelling theChronic Lyme Disease Myth
By Melissa M. Kemperman, M.P.H., Johan S. Bakken, M.D., Ph.D., and Gary R. Kravitz, M.D
(exceprts)
Chronic Lyme Disease
Some patients, advocates, and practitioners apply the term chronic Lyme disease to a broad set of persistent and nonspecific complaints including fatigue, myalgias, arthralgias, headache, and memory loss. The topic was recently reviewed by Feder et al., who proposed that chronic Lyme disease comprises multiple diagnostic categories, one of which is post-Lyme disease syndrome.18 Other patients who believe they have chronic Lyme disease may be seeking an alternative explanation to an already-diagnosed chronic illness such as multiple sclerosis or ankylosing spondylitis.
According to Feder et al., the chronic Lyme disease diagnosis also has been applied to patients with multiple nonspecific systemic complaints who lack any objective clinical findings of Lyme disease and have negative serologic studies for the condition.18 Without laboratory evidence of B. burgdorferi infection, these patients’ complaints are unlikely to be caused by Lyme disease. In addition, patients with chronic subjective symptoms who have antibody to B. burgdorferi may claim to have chronic Lyme disease. Without objective clinical findings, however, the positive predictive value of Lyme disease serology is low.18 These patients may have a positive IgM immunoblot or a few (<5/10) positive bands on IgG immunoblot, neither of which is compatible with late manifestations of Lyme disease.
For these reasons, the term chronic Lyme disease is a misnomer.18 Well-intentioned physicians often reinforce a patient’s fixation on the diagnosis by empirically prescribing antibiotics for those with nonspecific symptoms and negative or nondiagnostic Lyme serology or those with nonspecific symptoms and positive Lyme disease serology. Providers sometimes send blood samples to “Lyme specialty” laboratories that perform serologic tests interpreted by criteria that are not evidence-based. When the symptoms persist in spite of oral antibiotics, the patient often seeks additional information on the Internet or from alternative sources, much of which is inaccurate.20 This often leads to further courses of antibiotic treatment without demonstrable clinical benefit, a problem that underscores the need for careful clinical evaluation during the initial patient visit.
Antibiotic Therapy and Chronic Lyme Disease
Complaints of chronic Lyme disease rarely warrant new or continued antimicrobial therapy directed against B. burgdorferi. However, patients who are diagnosed with chronic Lyme disease frequently undergo long-term courses of oral or parenteral antibiotics.
The medical research community, including the IDSA, has thoroughly examined and refuted the case for long-term antibiotic treatment of patients with persistent symptoms attributed to Lyme disease.3,21 Four recent trials have failed to demonstrate any lasting benefits of prolonged antibiotic therapy for patients with post-Lyme disease syndrome.8,9,22,23 Because persistent symptoms in this population are not the result of active infection with B. burgdorferi, nonantimicrobial effects, such as the placebo effect or the anti-inflammatory activity of some antibiotics (eg, tetracycline and its derivatives), may explain transitory improvements during antibiotic therapy.18
In the absence of direct antimicrobial benefit, the risk of serious adverse effects outweighs any benefits of long-term antibiotic administration. In 1999, a 30-year-old Iowa woman died from septic embolic complications of an infected central venous catheter used for long-term IV antibiotic treatment of purported chronic Lyme disease.24 In a recent trial examining the efficacy of a 12-week course of either IV ceftriaxone or placebo for patients with post-Lyme disease syndrome, 6 of 23 (26%) patients given IV ceftriaxone experienced adverse events, including venous thrombosis, allergic reactions, or cholecystitis; in addition, 1 of 14 (7%) patients on IV placebo developed a systemic staphylococcal infection.22 Reports of other major adverse events associated with Lyme disease treatment have included antibiotic-associated Clostridium difficile infection, septic thrombophlebitis, neutropenia, serum sickness, jaundice, IV catheter-associated bloodstream infection, anaphylaxis, pulmonary embolism, and gastrointestinal bleeding.8,23,25
Patients who believe they have chronic Lyme disease frequently undergo other unproven and potentially dangerous treatments. The IDSA guidelines recommend against the following therapies for Lyme disease: combined antimicrobial therapies, pulsed-dosing, unproven antibiotics such as telithromycin or metronidazole, anti-babesiosis or anti-Bartonella treatment, hyperbaric oxygen therapy, fever therapy, IV immunoglobulin, ozone, cholestyramine, IV hydrogen peroxide, nutritional supplements, or injections of magnesium or bi****h.3
Addressing Patients’ Needs
Primary care physicians and specialists alike may encounter a number of diagnostic and treatment challenges when patients present with nonspecific symptoms they believe are caused by Lyme disease. Clinicians seeing patients with nonspecific symptoms should evaluate them for a history of blacklegged tick exposure before symptom onset, document objective manifestations of Lyme disease, and confirm the clinical suspicion of active infection with B. burgdorferi using validated serologic testing methods. Interpretation of serologic findings must be made in the context of the presenting stage of illness. Without a more likely alternative diagnosis, Lyme disease diagnosed by this method should be treated according to established guidelines unless the patient has already undergone appropriate treatment.3 For patients with post-Lyme disease syndrome, a clinician should verify that the previous treatment was appropriate and in accordance with current recommendations. In the absence of positive serologic evidence or objective clinical findings, clinicians should avoid making a tentative diagnosis of Lyme disease, as empirical treatment may cement the diagnosis in the patient’s mind and hamper further diagnostic efforts. Instead, they should explore other explanations for the patient’s complaints such as fibromyalgia, depression, or inflammatory rheumatologic disorder.
Dissuading patients who are convinced that they have chronic Lyme disease may be difficult. It often means disagreeing with another physician, the content of a website valued by the patient, or the opinions of a Lyme disease support group. To redirect a patient away from this diagnosis, the clinician should engage the patient in a straightforward yet empathetic conversation about Lyme disease diagnosis, treatment, and prognosis. With post-Lyme disease patients, the clinician must explain that it may take weeks or months for their headaches, achiness, fatigue, and other subjective symptoms to resolve and that this delay does not mean that treatment has failed. Clinicians should also explain the hazards associated with unnecessary antibiotic therapy, especially when administered intravenously. As patients increasingly turn to the Internet for information, they should be encouraged to seek out websites that provide evidence-based information about the diagnosis and treatment of Lyme disease such as those provided by the CDC, the Minnesota Department of Health, or Mayo Clinic and be cautioned about the multitude of sites that advocate unproven therapies.20 It is important to make it clear that rejection of a chronic Lyme disease diagnosis is not a denial of patients’ symptoms and concerns, as being perceived as dismissive could further encourage patients to pursue illegitimate therapies.
Finally, clinicians should guide these patients toward appropriate management of their complaints.18,26 This includes providing palliation of specific symptoms and conducting a thorough diagnostic work-up to determine the etiology of complaints, if one has not already been done. Some patients may also benefit from a psychiatric evaluation.
Conclusion
Patients with nonspecific symptoms ascribed to chronic Lyme disease pose special challenges and opportunities for physicians. When working with these patients, it is important to evaluate their complaints, perform laboratory tests, screen for tick exposure, and consider other disorders as well. Aspects of Lyme disease diagnosis and treatment should be clearly discussed, and patients should be directed toward legitimate sources of information. Prolonged or repeated courses of antibiotic therapy for these patients are ineffective and can put them at risk for dangerous complications. To avoid leaving patients who experience persistent symptoms feeling disregarded or alienated by mainstream medicine, their management should be approached in a collaborative, empathetic, and reassuring manner. MM